Literature DB >> 29588767

Basic Principles of Health Economics Applied - How to Assess if Transcatheter Aortic Valve Implantation is Worth the Investment.

Matthias Brunn1, Isabelle Durand-Zaleski2.   

Abstract

This article attempts to present some highlights from the rich economic literature pertaining to interventional cardiology and transcatheter aortic valve implantation (TAVI). There are currently more questions than answers, not surprisingly given the pace of technological change in interventional cardiology. For clinicians who work in a strictly regulated environment and have limited control over their use of medical technologies, this article will hopefully shed some light on the motives for policy decisions. For clinicians who make decisions on the resources used to treat their patients, it aims to provide the means of looking for evidence that will allow for informed decisions from both clinical and economic perspectives.

Entities:  

Keywords:  Health economics; cost-effectiveness; economic evaluation; transcatheter aortic valve implantation

Year:  2013        PMID: 29588767      PMCID: PMC5808588          DOI: 10.15420/icr.2013.8.2.135

Source DB:  PubMed          Journal:  Interv Cardiol        ISSN: 1756-1485


  19 in total

1.  Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement.

Authors:  Maureen Watt; Stuart Mealing; James Eaton; Nicolo Piazza; Neil Moat; Pascale Brasseur; Stephen Palmer; Rachele Busca; Mark Sculpher
Journal:  Heart       Date:  2011-11-10       Impact factor: 5.994

2.  Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.

Authors:  Martin B Leon; Craig R Smith; Michael Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; David L Brown; Peter C Block; Robert A Guyton; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Pamela S Douglas; John L Petersen; Jodi J Akin; William N Anderson; Duolao Wang; Stuart Pocock
Journal:  N Engl J Med       Date:  2010-09-22       Impact factor: 91.245

3.  Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B).

Authors:  Matthew R Reynolds; Elizabeth A Magnuson; Kaijun Wang; Yang Lei; Katherine Vilain; Joshua Walczak; Susheel K Kodali; John M Lasala; William W O'Neill; Charles J Davidson; Craig R Smith; Martin B Leon; David J Cohen
Journal:  Circulation       Date:  2012-02-03       Impact factor: 29.690

Review 4.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

5.  Two-year outcomes after transcatheter or surgical aortic-valve replacement.

Authors:  Susheel K Kodali; Mathew R Williams; Craig R Smith; Lars G Svensson; John G Webb; Raj R Makkar; Gregory P Fontana; Todd M Dewey; Vinod H Thourani; Augusto D Pichard; Michael Fischbein; Wilson Y Szeto; Scott Lim; Kevin L Greason; Paul S Teirstein; S Chris Malaisrie; Pamela S Douglas; Rebecca T Hahn; Brian Whisenant; Alan Zajarias; Duolao Wang; Jodi J Akin; William N Anderson; Martin B Leon
Journal:  N Engl J Med       Date:  2012-03-26       Impact factor: 91.245

6.  Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis: a Canadian perspective.

Authors:  Brett Doble; Gord Blackhouse; Ron Goeree; Feng Xie
Journal:  J Thorac Cardiovasc Surg       Date:  2012-07-11       Impact factor: 5.209

7.  Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A).

Authors:  Matthew R Reynolds; Elizabeth A Magnuson; Kaijun Wang; Vinod H Thourani; Mathew Williams; Alan Zajarias; Charanjit S Rihal; David L Brown; Craig R Smith; Martin B Leon; David J Cohen
Journal:  J Am Coll Cardiol       Date:  2012-07-18       Impact factor: 24.094

8.  Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk.

Authors:  Christopher J L Murray; Jeremy A Lauer; Raymond C W Hutubessy; Louis Niessen; Niels Tomijima; Anthony Rodgers; Carlene M M Lawes; David B Evans
Journal:  Lancet       Date:  2003-03-01       Impact factor: 79.321

9.  Registry of transcatheter aortic-valve implantation in high-risk patients.

Authors:  Martine Gilard; Hélène Eltchaninoff; Bernard Iung; Patrick Donzeau-Gouge; Karine Chevreul; Jean Fajadet; Pascal Leprince; Alain Leguerrier; Michel Lievre; Alain Prat; Emmanuel Teiger; Thierry Lefevre; Dominique Himbert; Didier Tchetche; Didier Carrié; Bernard Albat; Alain Cribier; Gilles Rioufol; Arnaud Sudre; Didier Blanchard; Frederic Collet; Pierre Dos Santos; Nicolas Meneveau; Ashok Tirouvanziam; Christophe Caussin; Philippe Guyon; Jacques Boschat; Herve Le Breton; Frederic Collart; Remi Houel; Stephane Delpine; Geraud Souteyrand; Xavier Favereau; Patrick Ohlmann; Vincent Doisy; Gilles Grollier; Antoine Gommeaux; Jean-Philippe Claudel; Francois Bourlon; Bernard Bertrand; Eric Van Belle; Marc Laskar
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

10.  Cost of transcatheter aortic valve implantation and factors associated with higher hospital stay cost in patients of the FRANCE (FRench Aortic National CoreValve and Edwards) registry.

Authors:  Karine Chevreul; Matthias Brunn; Benjamin Cadier; Georges Haour; Hélène Eltchaninoff; Alain Prat; Alain Leguerrier; Didier Blanchard; Gérard Fournial; Bernard Iung; Patrick Donzeau-Gouge; Christophe Tribouilloy; Jean-Louis Debrux; Alain Pavie; Martine Gilard; Pascal Gueret
Journal:  Arch Cardiovasc Dis       Date:  2013-04-24       Impact factor: 2.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.